However, many physicians are beginning to prescribe readily available COX2 inhibitor anti-inflammatory drugs, Celebrex or Vioxx, to their patients as a complement to their current therapy. The principle is to retard tumor growth with an antiangiogenic drug while killing existing cells with chemotherapy. During the first three months, five of the six patients had no progression or new tumor growth. All six were still alive after treatment up to 21 months later. Serum copper levels are often elevated when there is malignant tumor progression in cancers of the breast according to an article published in the Journal of Surgical Oncology, vol.
Copper is required for the function of angiogenesis.
Other researchers have met with success employing other copper reducing substances. Captopril has also been used successfully in humans to achieve tumor reduction, and is known to be a copper chelating agent. A Phase II trial with tetrathiomolybdate is now underway at the University of Michigan. Currently, a clinic in Mexico, Bio Pulse International, is offering IHT as part of its cancer protocol. The average number of treatments that a patient might receive at Bio Pulse is 50, administered over a period of five weeks or more.